Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board

Arch Biopartners appoints Patrick Vink as chairman of the board

Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease

Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide

Arch Biopartners Says Toronto's St Mike's Hospital Begins Patient Dosing In Phase II LSALT Peptide Trial

Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

Arch Biopartners Arranges Non-Brokered Private Placement

Arch Biopartners Closes Non-Brokered Private Placement

Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI

Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial